Show simple item record

dc.contributor.authorLee, L-Y
dc.contributor.authorGarland, SM
dc.date.accessioned2020-12-21T01:36:50Z
dc.date.available2020-12-21T01:36:50Z
dc.date.issued2017
dc.identifier.citationLee, L. -Y. & Garland, S. M. (2017). Human papillomavirus vaccination: the population impact.. F1000Res, 6, pp.866-. https://doi.org/10.12688/f1000research.10691.1.
dc.identifier.issn2046-1402
dc.identifier.urihttp://hdl.handle.net/11343/256583
dc.description.abstractWe currently have the knowledge and experience to prevent much of human papillomavirus (HPV)-related disease burden globally. In many countries where prophylactic HPV vaccination programs have been adopted as highly effective public health programs with good vaccine coverage, we are already seeing, in real-world settings, reduction of vaccine-related HPV-type infections, genital warts and cervical pre-cancers with potential reductions in vulvar, vaginal and anal pre-cancers. Moreover, we are seeing a change in cervical screening paradigms, as HPV-based screening programs now have strong evidence to support their use as more sensitive ways to detect underlying cervical abnormalities, as compared with conventional cervical cytology. This article describes the impact of prophylactic vaccination on these outcomes and in settings where these vaccines have been implemented in national immunisation programs. Given the successes seen to date and the availability of essential tools, there has been a global push to ensure that every woman has access to effective cervical screening and every girl has the opportunity for primary prevention through vaccination. A gender-neutral approach by offering vaccination to young boys has also been adopted by some countries and is worthy of consideration given that HPV-related cancers also affect males. Furthermore, vaccination of young boys has the advantage of reducing the risk of HPV transmission to sexual partners, lowering the infectious pool of HPV in the general population and ultimately HPV-related diseases for both genders. Therefore, it is appropriate that all countries consider and promote national guidelines and programs to prevent HPV-related diseases.
dc.languageeng
dc.publisherF1000 Research Ltd
dc.titleHuman papillomavirus vaccination: the population impact.
dc.typeJournal Article
dc.identifier.doi10.12688/f1000research.10691.1
melbourne.affiliation.departmentObstetrics and Gynaecology
melbourne.source.titleF1000Research
melbourne.source.volume6
melbourne.source.pages866-
dc.rights.licenseCC BY
melbourne.elementsid1225156
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473416
melbourne.contributor.authorWark, Suzanne
dc.identifier.eissn2046-1402
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record